Owkin is using artificial intelligence to identify new treatments and diagnostics. Cancer is a highly heterogeneous disease, with one cancer tissue containing many subtypes that may respond differently to treatments. By exploiting this additional layer of information that can be gathered from pathology slides, Owkin is offering solutions to give healthcare providers a fuller picture of a patient’s disease such that more patients can benefit from targeted therapies. However, Owkin is also using AI to identify new drug candidates, de-risk and accelerate clinical trials as well as building diagnostic solutions.

Owkin

Intern - Biomed Discovery

People Ops Apprentice

Data Engineer

FP&A Business Partner

Legal Intern

Owkin and Tribun Health Launch Strategic Partnership to Accelerate Access to AI Solutions for Diagnosis and Pharma Research - Newswire

 Systems and methods for determining breast cancer prognosis and associated … 

CORRECTING and REPLACING Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin - Business Wire

PortrAIt

Partner Spotlight: Owkin and Sanofi embrace the “golden era” of precision medicine with AI - Sanofi

Owkin unveils new insights for digital pathology and AI solutions in healthcare - European Pharmaceutical Manufacturer

HuggingFace

 AI in Healthcare: Key Innovations and 5 Companies to Watch in 2025 

Owkin has been named one of Forbes’ AI 50April 11, 2024

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology - PMLiVE

Press release

Paris
14/16 Bd Poissonnière, 75009 Paris

 TechBio Firm Owkin and AWS Team on GenAI and Drug Discovery 

SRATTAExplore SRATTA attack in federated learning, a risk to secure data sharing, and Owkin’s strategies to strengthen defenses in healthcare research.[03:35]August 23, 2023

Owkin launches AI discovery program for medical breakthroughs - Scientific Computing World

BMS Enlists Owkin’s AI/ML Tech to Improve Clinical Trials - BioSpace

Stratification biomarkersThese biomarkers predict the best treatment for each patient by analyzing subgroups of good and bad responders.They are used as AI patient selection tools to predict the best treatment, create surrogate markers and to steer research for future targets.Read case studyStratification biomarkersThese biomarkers predict the best treatment for each patient by analyzing subgroups of good and bad responders.They are used to better predict the response to treatment, create surrogate markers and to steer research for future targets.Read case study

 AZ and Owkin partner on AI to speed up BRCA testing 

 Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline 

10 AI startup operators to watch in Europe - Sifted

 Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors 

State of the Nation: Opportunities and Challenges for Digital Pathology and AI Solutions

Owkin x BSW | Partners in ScienceDiscover how Owkin’s AI algorithms help diagnose endometrial cancer by analyzing digitized pathology images, driving advancements in AI diagnostics.[01:52]February 12, 2025

Merck taps Owkin’s AI to boost microsatellite testing of GI cancers - Fierce Biotech

🎤 Dr. Ingo Ringshausen, Principal Investigator at University College London and Consultant Haematologist at UCLH, joined the London Standard Tech & Science Daily podcast to share how K Navigator, Owkin’s new agentic AI co-pilot for scientists, is already transforming his day-to-day research. 🔬 

It’s a fascinating conversation - listen here: https://lnkd.in/eY6t3nad

 Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation 

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors - BioSpace

Ex-Google DeepMind and Owkin scientists team up to create Bioptimus to build the first universal AI foundation model for biology - Business Wire

Owkin announces Owkin K1.0 Turbigo, a cutting-edge operating system to create the first AGI for biology, at JP Morgan Healthcare ConferenceJanuary 13, 2025

Federated Learning Market Is Booming So Rapidly | Microsoft, Cloudera, Owkin - openPR.com

 Digital Clinical Research Platform For Drug Development Owkin Raises $180M At A Unicorn Valuation 

TargetMATCHExplore how Owkin’s TargetMATCH uses AI to identify therapeutic targets and patient subgroups, advancing drug discovery with precision.[2:37]April 5, 2024

Entalpic raises €8.5 Million to pioneer AI solutions for decarbonizing industrial chemistry - Cathay Capital

MOSAIC Window

🚀 Exciting news – congratulations to GENCI, CNRS, and IDRIS (CNRS) on the recent extension of the Jean Zay cluster, another leap for scientific and AI research in France. Jean Zay is a supercomputer, named after the historic French Minister of National Education and Fine Arts, and hosted at IDRIS (CNRS), a national computing center for CNRS.

At Owkin, we’ve greatly benefited from Jean Zay’s compute power over the past 5 years, leveraging it to advance our state-of-the-art foundation models for histopathology.

“As a public service we are very proud at GENCI and IDRIS (CNRS) to support such leading edge AI projects from Owkin toward the use of SOTA #AI models in health and biology with our supercomputer Jean Zay and all the support services provided. This will be accelerated soon with the rise of AI Factory France, stay tuned !” – Stephane Requena, CTO of GENCI

We extend a big thank you to GENCI, CNRS, and IDRIS for the continued collaboration — we're proud to contribute research to this initiative and promote open science within the French research community.

#AI #frenchtech

📘 Excited to share that our collaborative work with CHUV | Lausanne university hospital evaluating spatial omics methods for studying tumor biology is now published by Nature Communications!

We benchmarked Visium, Chromium, and GeoMx DSP for transcriptomic analysis of archived tumors from patients with breast cancer, non-small cell lung cancer, and Diffuse Large B-Cell Lymphoma (DLBCL)— revealing key insights into platform performance and tumor heterogeneity.

Our findings suggest that Visium and Chromium are better suited for high-throughput, exploratory projects, while GeoMx is a better fit for targeted studies.

This study played a key role in guiding technology selection for our ongoing MOSAIC research project.

Read the open access paper: https://lnkd.in/gVY_S4pf

Predicting histological response to NACT in TNBCHealthChain is a collaborative research project between Owkin federated research network partners using federated learning.Machine learning models were trained on histology slides and dermoscopy images across for institutions to predict treatment response in breast cancer and melanoma patients. The resultant model helps oncologists better predict treatment response in breast cancer.Read the paperPredicting histological response to NACT in TNBCHealthChain is a collaborative research project between Owkin federated research network partners using federated learning.Machine learning models were trained on histology slides and dermoscopy images across for institutions to predict treatment response in breast cancer and melanoma patients. The resultant model helps oncologists better predict treatment response in breast cancer.Read the paper


                Owkinews: What Happened in May?
              

The unicorns that could be due a fundraise in 2025 - Sifted

Press releaseOwkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcareDecember 12, 2024

EY features Owkin's CEO Thomas Clozel in the "Grow Fast, Now What?" podcast (FR)February 18, 2025

 Ex-Google DeepMind and Owkin scientists team up to create Bioptimus to build the first universal AI foundation model for biology 

Power and significance: clinical trial benefits with advanced covariate adjustment - Nature.com

We're excited to welcome Nadia Arfaoui to Owkin as our new VP of Product - Diagnostics.

With over a decade of experience in diagnostics and life sciences, Nadia brings a wealth of expertise to our team.

Previously serving as Chief Product & Technical Officer at BioSerenity, she led the development of cutting-edge healthcare solutions that directly improved patient outcomes, aligning product and technical strategies with business growth. In this new role, she will leverage this experience to shape our product vision and deliver impactful, high-value solutions to healthcare professionals and patients.

AI diagnosticsOwkin’s AI diagnostics streamline cancer care, enhancing pathology insights for targeted therapies and improved patient outcomes.[02:50]April 5, 2022

Owkin in depth: pushing boundaries in AI researchMarch 27, 2025

GenevaRue François-Bellot 6, 1206

 Amgen, Owkin study shows cardiac-predicting AI outperforms traditional clinical methods 

HCCnet


              Owkinews: what happened in December?
            

Penticton Indian Band's En'owkin Centre hosting special craft fair once again - Penticton News - Castanet

Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients - Business Wire

Merck and Owkin Partner on AI-Powered Precision Cancer Tests - Inside Precision Medicine

We’re taking the next step in our collaboration with MSD, entering the product development phase of MSIntuit® for Endometrial and Gastric cancers.

Following the success of MSIntuit® CRC for colorectal cancer, these AI solutions aim to support MSI screening, streamline case management, speed up treatment decisions, and facilitate access to immunotherapy.

Learn more: https://lnkd.in/ePCEybUM

The products are being developed within the framework of the PortrAIt consortium. Learn more: www.portraitpathology.ai

Owkin launches global patient data sharing network for ...

Top execs from French AI unicorn Owkin are launching a new startup to build an LLM for biotech - Sifted

SubstraThe most proven federated learning software designed for healthcare research.Substra is a ready-to-use, open source federated learning (FL) software developed by Owkin, now hosted by the Linux Foundation for AI and Data. Substra enables the training and validation of machine learning models on distributed datasets. It includes a flexible Python interface and a web application to run federated learning training at scale.Find out more

 Jean-Jacques Bienaimé Appointed Chairman of the Board at Owkin 

Owkin's MSIntuit CRC wins Best Medical Technology Prix Galien AwardJuly 4, 2024

 A vision for the hospital of the future 

Owkin and Proscia expand access to AI pre-screening for colorectal cancer patientsNovember 19, 2024

Former BioMarin CEO Bienaimé named chair of Owkin - BioCentury

Owkin launches AI research copilot - Scientist Live

Owkin is 'fueling breakthroughs' with ATLANTIS AI initiative to unify biomedical data - FirstWord Pharma

Join expert pathologists Magali Lacroix-Triki from Gustave Roussy, savitri krishnamurthy from MD Anderson Cancer Center, and Valentin Gaury for our upcoming webinar ‘Breast Cancer Recurrence Risk Assessment from Digitized H&E with RlapsRisk® BC, a Clinically Validated AI Prognostic Solution.’

Discover groundbreaking findings on RlapsRisk® BC, an innovative AI-driven product that assesses breast cancer recurrence risk directly from digital pathology slides.

The speakers will cover everything from the impact of AI-powered digital pathology on outcome prediction to real-world implementation experiences—plus head-to-head comparisons with clinical scores and molecular tests.

📅 Don’t miss this opportunity to explore the future of breast cancer prognostic testing. Register here: https://lnkd.in/eWGmtXbe

Owkin bringt K Navigator auf den Markt, einen bahnbrechenden agentenbasierten Co-Piloten, der Durchbrüche in der biomedizinischen Forschung um das 20-fache beschleunigt - Eagle-Tribune

Watch Replay

Precision medicineDiscover how Professor Miriam Merad utilizes AI and precision medicine at Mount Sinai to revolutionize diagnostics and drug development in partnership with Owkin.[04:02]February 13, 2023

Owkin, Proscia Partner to Streamline MSI Testing for Colorectal Cancer - - HIT Consultant

Owkin Appoints Graeme Bell as Chief Financial OfficerMay 5, 2025

 AI-assisted biotech startup Owkin becomes latest French unicorn 

Download our whitepaper

An LLM for biotech: French startup Bioptimus raises $35m seed - Sifted

 BMS Enlists Owkin's AI/ML Tech to Improve Clinical Trials 

The role of AI in pathology goes beyond innovation, it’s transforming diagnostics. Following the final chapter of our From Slides to Devices series, Dr. Isabelle Birtwisle shares why deploying AI in pathology is critical.

🔍 Read her insights: https://lnkd.in/efiMN5gW

Owkin lance K Navigator, un copilote agentique révolutionnaire destiné à multiplier par 20 les avancées de la recherche biomédicale - standard-journal.com

Voice as a biomarkerOwkin and 12 partners are using Substra to train machine learning models on the largest distributed clinical dataset of voice data.The project aims to identify biomarkers from voice data to create low-cost diagnostic tools that will be used alongside other clinical methods.Read moreVoice as a biomarkerOwkin and 12 partners are using Substra to train machine learning models on the largest distributed clinical dataset of voice data.The project aims to identify biomarkers from voice data to create low-cost diagnostic tools that will be used alongside other clinical methods.Read more

Is This the Era of AI Diagnostics? Virtual Event | Register now. - STAT

Owkin and Proscia expand access to AI pre-screening for colorectal cancer patients - Scientific Computing World

Drug discoveryExplore how Owkin’s AI engines transform drug discovery with patient data and precision medicine insights.[03:25]May 16, 2023

Press releaseOwkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcareRead the article

TechBio Firm Owkin and AWS Team on GenAI and Drug Discovery - PYMNTS.com

 Exclusive: Medical AI startup Owkin just secured $80 million as it gears up to launch a drug trial with the pharmaceutical giant Bristol Myers Squibb 

Schmauch  et al. 2020

Talk to our product team

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Business Wire

 Owkin welcomes leading immuno-oncology professor as Chief Medical Officer and senior pharma exec as SVP Data Science 

TargetMATCH: Owkin’s AI discovery engineDiscover Owkin's TargetMatch, leveraging 50 petabytes of multimodal data from 30M patients to revolutionize AI-driven therapeutic target discovery.[01:38]May 28, 2024

Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer - Business Wire

Explore our open access publications, data and modelsOpen scienceDiscover Owkin's open source repositories, datasets, models and preprints.Find out more

Owkin’s CEO, Thomas Clozel named in Le Figaro’s top 7 french leaders in AIFebruary 6, 2025Le Figaro

Les Echos covers Owkin’s role in AI in healthcare for the AI Action Summit February 9, 2025Les Echos


              Unlocking the mysteries of complex biological systems with agentic AI
            

Covariate adjustmentLearn how Owkin's data-driven covariate adjustment methodology boosts statistical power and supports regulatory submissions for oncology trials. [02:21]May 25, 2022

Boston245 Main Street Cambridge MA 02142

Ex-BioMarin CEO Bienaimé re-emerges at Owkin - pharmaphorum

 FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape 

Owkin collaborates with MSD to assess the impact of MSIntuit® CRC to accelerate patient identification for therapeutic decisions August 19, 2024

 Top execs from French AI unicorn Owkin are launching a new startup to build an LLM for biotech 

Wrapping up another fantastic AACR 2025 ✨ 

Our Senior Manager of Commercial Strategy & Operations, Ariane Peyret, PhD, shares her insights from the conference, covering everything from the future of cancer research and the evolution of ADCs to the unveiling of our AI co-pilot, K Navigator.

If you are planning to be at ASCO, please come and meet us at booth #22155. Book a meeting here: https://lnkd.in/eQuqf_AD

Read the blog: https://lnkd.in/eCRNS27k

Owkin

About: